抗糖尿病薬は,Cdk5によって肥満に関連したPPARgammaのリン酸化を阻害する
Jang Hyun Choi1, Alexander S Banks, Jennifer L Estall
1Department of Cancer Biology and Division of Metabolism and Chronic Disease, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Nature
|July 24, 2010
まとめ
高脂肪食はCdk5を活性化し,脂肪組織内のPPARgammaをリン酸化する. これは遺伝子発現を妨害し,アディポネクチンを減少させ,インスリン抵抗性につながる. このリン酸化を阻害することで,新しい抗糖尿病治療法を提供することができる.
科学分野:
- メタボリック疾患の研究
- 分子内分泌学は分子内分泌学である.
- アディポス組織生物学
背景:
- 肥満はインスリン抵抗性や脂肪細胞の遺伝子発現の変化と関連しています.
- ペロキシソーム増殖器活性化受容体ガンマ (PPARgamma) は,脂肪細胞機能の重要な調節体である.
- 肥満に関連する代謝機能障害における特定のタンパク質変異の役割は,活発な研究分野である.
研究 の 目的:
- 肥満に起因する代謝変化におけるサイクリン依存キナーゼ5 (Cdk5) の役割を調査する.
- 脂肪組織におけるPPARgamma活性と遺伝子発現に対するCdk5の影響を決定する.
- インスリン抵抗性に対するCdk5媒介PPARgammaリン酸化を標的とした治療の可能性を調査する.
主な方法:
- 高脂肪の餌を用いたマウスの肥満誘導.
- 脂肪組織におけるタンパク質キナーゼCdk5活性化とPPARガンマリン酸化の分析.
- 遺伝子発現プロファイリングは,アディポネクチンを含む不調の遺伝子を特定するために行われます.
- 抗糖尿病PPARガマリンガンド (ロシグリタゾン,MRL24) を使用したインビトロおよびインビボ実験.
主要な成果:
- 高脂肪食は脂肪組織におけるCdk5を活性化し,セルリン273.3でPPARガンマリン酸化を引き起こした.
- PPARガンマリン酸化はアディポゲン能力には影響しなかったが,肥満に関連した遺伝子の調節を乱し,アディポネクチンが減少した.
- 抗糖尿病PPARガマリンガンドは,転写アゴニズムとは無関係にCdk5媒介PPARガマリン酸化を阻害した.
- ロシグリタゾンのPPARガマリン酸化抑制は,肥満患者の抗糖尿病効果と相関していた.
結論:
- Cdk5媒介によるPPARgammaのリン酸化は,インスリン抵抗性の病原性に関与しています.
- Cdk5媒介のPPARgamma変異をターゲットにすることは,インスリン抵抗性に対する新しい治療戦略を提供します.
- 次世代の抗糖尿病薬の開発は,PPARガンマリン酸化を調節することに焦点を当てることができる.
さらに関連する動画
関連する概念動画
GPCRs Regulate Adenylyl Cylase Activity
6.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
cAMP-dependent Protein Kinase Pathways
7.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
958
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K


